JP2005509622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509622A5 JP2005509622A5 JP2003535774A JP2003535774A JP2005509622A5 JP 2005509622 A5 JP2005509622 A5 JP 2005509622A5 JP 2003535774 A JP2003535774 A JP 2003535774A JP 2003535774 A JP2003535774 A JP 2003535774A JP 2005509622 A5 JP2005509622 A5 JP 2005509622A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- hydrogen
- compound according
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- -1 benzyloxy, hydroxy Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 238000010640 amide synthesis reaction Methods 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0124928.3A GB0124928D0 (en) | 2001-10-17 | 2001-10-17 | Chemical compounds |
| PCT/EP2002/011570 WO2003032970A1 (en) | 2001-10-17 | 2002-10-16 | 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005509622A JP2005509622A (ja) | 2005-04-14 |
| JP2005509622A5 true JP2005509622A5 (enExample) | 2006-01-05 |
Family
ID=9924024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535774A Pending JP2005509622A (ja) | 2001-10-17 | 2002-10-16 | ５’−カルバモイル−２’−メチル−１，１’−ビフェニル−４−カルボキサミド誘導体及びそのｐ３８キナーゼ阻害薬としての使用 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1435933A1 (enExample) |
| JP (1) | JP2005509622A (enExample) |
| GB (1) | GB0124928D0 (enExample) |
| WO (1) | WO2003032970A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| BRPI0307351B8 (pt) | 2002-02-12 | 2021-05-25 | Smithkline Beecham Corp | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto |
| GB0209891D0 (en) | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
| GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| AU2004251668B2 (en) | 2003-06-03 | 2008-03-20 | Triad Therapeutics, Inc | 5-membered heterocycle-based p-38 inhibitors |
| GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| ES2393950T3 (es) | 2003-06-26 | 2013-01-02 | Novartis Ag | Inhibidores de la quinasa P38 con base en heterociclos de 5 miembros |
| DE602004017494D1 (de) * | 2003-07-25 | 2008-12-11 | Novartis Ag | Inhibitoren von p-38-kinase |
| GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0402138D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| EP1723132A1 (en) * | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| KR20200019263A (ko) * | 2004-09-02 | 2020-02-21 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| AR055271A1 (es) * | 2004-10-05 | 2007-08-15 | Smithkline Beecham Corp | Compuesto del acido bifenil carboxilico, composicion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para prepararlo |
| MX2007008290A (es) * | 2005-01-07 | 2008-02-15 | Synta Pharmaceuticals Corp | Compuestos para inflamacion y usos inmuno-relacionados. |
| US8518950B2 (en) | 2005-01-25 | 2013-08-27 | Synta Pharmaceuticals Corp. | 2-amido pyrazines for inflammation and immune related uses |
| AU2006290442B2 (en) * | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| RU2452729C2 (ru) * | 2005-09-16 | 2012-06-10 | Арроу Терапьютикс Лимитед | Бифенильные производные и их применение при лечении гепатита с |
| EP2038253A1 (en) * | 2006-05-30 | 2009-03-25 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| JP2010508288A (ja) | 2006-10-27 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物 |
| US9079858B2 (en) * | 2011-08-31 | 2015-07-14 | Amakem Nv | Rock kinase inhibitors |
| TW201609700A (zh) * | 2014-02-19 | 2016-03-16 | Ｈ 朗德貝克公司 | ２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶作爲ｂａｃｅ１抑制劑用於治療阿茲海默症 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| US20180244645A1 (en) | 2015-08-12 | 2018-08-30 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| WO2019071144A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| KR102298450B1 (ko) * | 2021-01-29 | 2021-09-08 | (주)프레이저테라퓨틱스 | p38 MAP 키나아제 억제제로 항염증 활성을 나타내는 신규 화합물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2502764A1 (en) * | 1995-08-22 | 1997-03-06 | Japan Tobacco Inc. | Amide compounds |
| CA2359244C (en) * | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
-
2001
- 2001-10-17 GB GBGB0124928.3A patent/GB0124928D0/en not_active Ceased
-
2002
- 2002-10-16 JP JP2003535774A patent/JP2005509622A/ja active Pending
- 2002-10-16 EP EP02779491A patent/EP1435933A1/en not_active Withdrawn
- 2002-10-16 WO PCT/EP2002/011570 patent/WO2003032970A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511532A5 (enExample) | ||
| JP2005505618A5 (enExample) | ||
| JP2005511531A5 (enExample) | ||
| JP2005519932A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2005538100A5 (enExample) | ||
| JP2005508960A5 (enExample) | ||
| KR0167395B1 (ko) | 부신피질자극호르몬-방출인자 길항제로서의 피라졸로피리미딘 | |
| JP2007501831A5 (enExample) | ||
| RU2004120553A (ru) | Производные никотинамида, полезные в качестве р38-ингибиторов | |
| JP2005508967A5 (enExample) | ||
| JP2006523193A5 (enExample) | ||
| ZA200508158B (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
| JP2018525375A5 (enExample) | ||
| JP2004520285A5 (enExample) | ||
| JP2004517099A5 (enExample) | ||
| CN1152870A (zh) | 杂环化合物作为多巴胺d3配位体的用途 | |
| JP2007538092A5 (enExample) | ||
| CA2709786A1 (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | |
| WO2005047279A8 (en) | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | |
| RU2013138834A (ru) | N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2 | |
| JP2005508962A5 (enExample) | ||
| JP2006523192A5 (enExample) | ||
| CN1126472A (zh) | 5-ht4受体拮抗物 | |
| YU73502A (sh) | Farmaceutski aktivni derivati pirolidina |